- Home
- HZO vs CELC Comparison
HZO vs CELC Comparison
Compare HZO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HZO
- CELC
- Stock Information
- Founded
- HZO 1998
- CELC 2011
- Country
- HZO United States
- CELC United States
- Employees
- HZO N/A
- CELC N/A
- Industry
- HZO Auto & Home Supply Stores
- CELC Medical Specialities
- Sector
- HZO Consumer Discretionary
- CELC Health Care
- Exchange
- HZO Nasdaq
- CELC Nasdaq
- Market Cap
- HZO 450.3M
- CELC 440.0M
- IPO Year
- HZO 1998
- CELC 2017
- Fundamental
- Price
- HZO $25.21
- CELC $11.85
- Analyst Decision
- HZO Strong Buy
- CELC Strong Buy
- Analyst Count
- HZO 6
- CELC 5
- Target Price
- HZO $36.50
- CELC $30.80
- AVG Volume (30 Days)
- HZO 305.3K
- CELC 143.2K
- Earning Date
- HZO 07-24-2025
- CELC 08-13-2025
- Dividend Yield
- HZO N/A
- CELC N/A
- EPS Growth
- HZO N/A
- CELC N/A
- EPS
- HZO 2.44
- CELC N/A
- Revenue
- HZO $2,420,818,000.00
- CELC N/A
- Revenue This Year
- HZO $0.21
- CELC N/A
- Revenue Next Year
- HZO $3.78
- CELC N/A
- P/E Ratio
- HZO $10.24
- CELC N/A
- Revenue Growth
- HZO N/A
- CELC N/A
- 52 Week Low
- HZO $16.85
- CELC $7.58
- 52 Week High
- HZO $38.20
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- HZO 58.68
- CELC 52.40
- Support Level
- HZO $23.62
- CELC $11.28
- Resistance Level
- HZO $25.80
- CELC $12.54
- Average True Range (ATR)
- HZO 1.04
- CELC 0.67
- MACD
- HZO 0.07
- CELC -0.10
- Stochastic Oscillator
- HZO 76.93
- CELC 27.06
About HZO MarineMax Inc. (FL)
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.